Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1600 participants
OBSERVATIONAL
2026-01-01
2029-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Air Pollution and Daily Mobility of Pregnant Women Identification of Critical Windows of Exposure
NCT04725734
The Mechanism of Adverse Pregnancy Outcomes Influenced by Maternal Air Pollution Exposure
NCT04215406
Evaluating Pathophysiological Mechanisms of Acute and Chronic Heat Stress on Maternal and Fetal Health
NCT07326176
Relationship Between Multi-exposure to Noise and Air Pollution and the Onset of Hypertension Disorders During Pregnancy
NCT03261245
Bisphenol A Exposure, Ovarian Function and Assisted Reproductive Technology Outcome.
NCT02377219
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Case-control design The study includes 1600 participants, providing a substantial sample for analysis. The focus is on newborns (age 0), making the study particularly relevant for understanding factors and outcomes related to this very early stage of life. The sex of the participants is expected to be randomly distributed. A control arm of full-term neonates (\>37 weeks) will be recruited for a 1:2 ratio in Greece and Spain.
2. Personal Exposure Monitoring PEM Substudy:
The study consists of 150 mothers, with 50 from each location. All participants are females aged over 18 years. The sex of the participants is expected to be randomly distributed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Case-control design
The study includes 1600 participants, providing a substantial sample for analysis. The focus is on newborns (age 0), making the study particularly relevant for understanding factors and outcomes related to this very early stage of life. The sex of the participants is expected to be randomly distributed. A control arm of full-term neonates (\>37 weeks) will be recruited for a 1:2 ratio in Greece and Spain. ENVIRONAGE, Belgium, employs a nested case-control design, making use of its prospective cohort framework that is already in place.
No interventions assigned to this group
Personal Exposure Monitoring PEM Substudy
The study consists of 150 mothers, with 50 from each location. All participants are females aged over 18 years. The sex of the participants is expected to be randomly distributed.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Non-smoking mothers and no exposure to environmental (second-hand) smoke (smoking influences UFP measurements);
* ≥18 years old (mothers have to place sensors, mothers with childhood pregnancies may live at their parental home);
* Not expecting to terminate the pregnancy (no measurements of the child);
* Having resided in the geographical area of research for a minimum period of 1 year (to be eligible for modeling exposures).
Exclusion Criteria
* Pregnancy complications that limit exposure measurements in urine (because it may cause polyuria, for example, gestational diabetes);
* Known kidney disease (might influence exposure measurements in urine);
* Multiple pregnancy (twin or more pregnancies may have a higher risk for complications or preterm birth, no measurements in the last trimester).
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hasselt University
OTHER
Aristotle University Of Thessaloniki
OTHER
Instituto de Investigacion Sanitaria La Fe
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alba Ruiz Gaitán
MD, PhD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Instituto de Investigación Sanitaria La Fe
Valencia, Valencia, Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1011566
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
UPRISE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.